BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28891274)

  • 21. Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions.
    Guglielmi C; Scarpitta R; Gambino G; Conti E; Bellè F; Tancredi M; Cervelli T; Falaschi E; Cosini C; Aretini P; Congregati C; Marino M; Patruno M; Pilato B; Spina F; Balestrino L; Tenedini E; Carnevali I; Cortesi L; Tagliafico E; Tibiletti MG; Tommasi S; Ghilli M; Vivanet C; Galli A; Caligo MA
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biallelic NF1 inactivation in high grade serous ovarian cancers from patients with neurofibromatosis type 1.
    Courtney E; Chan SH; Li ST; Ishak D; Merchant K; Shaw T; Chay WY; Chin FHX; Wong WL; Wong A; Ngeow J
    Fam Cancer; 2020 Oct; 19(4):353-358. PubMed ID: 32405727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
    Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
    Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer susceptibility: current knowledge and implications for genetic counselling.
    Ripperger T; Gadzicki D; Meindl A; Schlegelberger B
    Eur J Hum Genet; 2009 Jun; 17(6):722-31. PubMed ID: 19092773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.
    Li J; Meeks H; Feng BJ; Healey S; Thorne H; Makunin I; Ellis J; ; Campbell I; Southey M; Mitchell G; Clouston D; Kirk J; Goldgar D; Chenevix-Trench G
    J Med Genet; 2016 Jan; 53(1):34-42. PubMed ID: 26534844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1.
    Noë M; Pea A; Luchini C; Felsenstein M; Barbi S; Bhaijee F; Yonescu R; Ning Y; Adsay NV; Zamboni G; Lawlor RT; Scarpa A; Offerhaus GJA; Brosens LAA; Hruban RH; Roberts NJ; Wood LD
    Mod Pathol; 2018 Oct; 31(10):1532-1538. PubMed ID: 29849115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
    Shahi RB; De Brakeleer S; Caljon B; Pauwels I; Bonduelle M; Joris S; Fontaine C; Vanhoeij M; Van Dooren S; Teugels E; De Grève J
    BMC Cancer; 2019 Apr; 19(1):313. PubMed ID: 30947698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception.
    Bychkovsky BL; Lo MT; Yussuf A; Horton C; Hemyari P; LaDuca H; Garber JE; Scheib R; Rana HQ
    Breast Cancer Res Treat; 2023 Jul; 200(1):63-72. PubMed ID: 36856935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
    Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
    Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.
    Kleibl Z; Kristensen VN
    Breast; 2016 Aug; 28():136-44. PubMed ID: 27318168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype.
    Yap YS; Munusamy P; Lim C; Chan CHT; Prawira A; Loke SY; Lim SH; Ong KW; Yong WS; Ng SBH; Tan IBH; Callen DF; Lim JCT; Thike AA; Tan PH; Lee ASG
    Breast Cancer Res Treat; 2018 Oct; 171(3):719-735. PubMed ID: 29926297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency of Pathogenic Germline Variants in
    Petridis C; Arora I; Shah V; Moss CL; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
    Cancer Epidemiol Biomarkers Prev; 2019 Jul; 28(7):1162-1168. PubMed ID: 31263054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A case of neurofibromatosis and breast cancer: loss of heterozygosity of NF1 in breast cancer.
    Güran S; Safali M
    Cancer Genet Cytogenet; 2005 Jan; 156(1):86-8. PubMed ID: 15588864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next-generation panel sequencing identifies
    Gieldon L; Masjkur JR; Richter S; Därr R; Lahera M; Aust D; Zeugner S; Rump A; Hackmann K; Tzschach A; Januszewicz A; Prejbisz A; Eisenhofer G; Schrock E; Robledo M; Klink B
    Eur J Endocrinol; 2018 Feb; 178(2):K1-K9. PubMed ID: 29158289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
    Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
    Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women.
    Kurian AW; Hughes E; Handorf EA; Gutin A; Allen B; Hartman AR; Hall MJ
    JCO Precis Oncol; 2017 Nov; 1():1-12. PubMed ID: 35172496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
    Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study.
    Li W; Shao D; Li L; Wu M; Ma S; Tan X; Zhong S; Guo F; Wang Z; Ye M
    J Ovarian Res; 2019 Aug; 12(1):80. PubMed ID: 31472684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?
    Angeli D; Salvi S; Tedaldi G
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.